ReviewJournal of clinical medicine2021
The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Pathogenic cytokines in thrombotic microangiopathies: molecular insights and therapeutic targets.Molecular medicine (Cambridge, Mass.) · 2025Review
- Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia-Pacific Perspective.Nephrology (Carlton, Vic.) · 2025Review
- Toward a Revised Definition of Thrombotic Microangiopathy.Kidney international reports · 2025Article
- Atypical Hemolytic Uremic Syndrome After Post-Abortion Infection: Case Report and Literature Review.International journal of women's health · 2025Article
- Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.Frontiers in pharmacology · 2025Article
- The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.International journal of molecular sciences · 2024Review
- A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.Kidney international · 2024Article
- Renal microangiopathy and immune complex glomerulonephritis induced by anti-tumour agents: A case report.Open life sciences · 2024Article
- The spectrum of thrombotic microangiopathy related to monoclonal gammopathy.Clinical kidney journal · 2024Article
- Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.Med (New York, N.Y.) · 2023Article
- Severe hypertension and (renal) thrombotic microangiopathy: solving the puzzle.Journal of nephrology · 2023Article
- Rare Variants in Complement Genes May Not Be That Rare After All.Kidney international reports · 2023Article
- Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry.Kidney international reports · 2023Article
- C3 Glomerulopathy and Thrombotic Microangiopathy: A "Hybrid" Phenotype.Kidney international reports · 2023Article
- Review of acute kidney injury and progression to chronic kidney disease in pediatric patients undergoing hematopoietic cell transplant.Frontiers in oncology · 2023Review
- A Life-Threating Postpartum Atypical Hemolytic-Uremic Syndrome with Multiorgan Involvement.Journal of clinical medicine · 2022Article
- Thrombotic microangiopathy in children.Pediatric nephrology (Berlin, Germany) · 2022Review
- Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy.Current issues in molecular biology · 2022Review
- Postsurgical Thrombotic Microangiopathy and Deregulated Complement.Journal of clinical medicine · 2022Article
- Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy (TMA) is a rare and potentially life-threatening condition that can be caused by a heterogeneous group of diseases, often affecting the brain and kidneys. TMAs should be classified according to etiology to indicate targets for treatment. Complement dysregulation is an important cause of TMA that defines cases not related to coexisting conditions, that is, primary atypical hemolytic uremic syndrome (HUS). Ever since the approval of therapeutic complement inhibition, the approach of TMA has focused on the recognition of primary atypical HUS. Recent advances, however, demonstrated the pivotal role of complement dysregulation in specific subtypes of patients considered to have secondary atypical HUS. This is particularly the case in patients presenting with coexisting hypertensive emergency, pregnancy, and kidney transplantation, shifting the paradigm of disease. In contrast, complement dysregulation is uncommon in patients with other coexisting conditions, such as bacterial infection, drug use, cancer, and autoimmunity, among other disorders. In this review, we performed a critical appraisal on complement dysregulation and the use of therapeutic complement inhibition in TMAs associated with coexisting conditions and outline a pragmatic approach to diagnosis and treatment. For future studies, we advocate the term complement-mediated TMA as opposed to the traditional atypical HUS-type classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.